Geron to shut down stem cell programs

14 November 2011
Today's announcement by the Geron Corporation to withdraw from the field of regenerative medicine is an example of how economic considerations and changes in corporate strategy can impact on the development of promising novel therapeuties with high risk, high payoff development trajectories. 

The action is certainly an argument for continued public support for translational and clinical research in this field, and it shows the importance of exploring new business models for development of such products.